### Accreditation Statement

In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### Credit Designation Statements

The University of Minnesota, Interprofessional Continuing Education designates this enduring material for a maximum of 36.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### DISCLOSURE STATEMENTS

It is the policy of the University Of Minnesota Office Of Continuing Professional Development to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals (including spouse/partner) who have influence over activity content are required to disclose to the learners any financial relationships with a commercial interest related to the subject matter of this activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on, patients. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. Specific disclosure information for each presenter, course director, and planning committee member will be shared with the learner prior to the presenter’s presentation. Persons who fail to complete and sign this form in advance of the activity are not eligible to be involved in this activity.

#### Planning Committee

**Planning Committee and Faculty**

Under the direction of Dr. William Stauffer, the course content was identified and drawn based upon input from the following advisory members. Unless otherwise noted, individuals did not indicate any financial relationships and do not intend to discuss off-label/investigative use of a commercial product or device.

- Brett Hendel-Paterson, MD, CTropMed®
- Manoj Ray, MD
- Kristina Krohn, MD
- Meghan Rothenberger, MD
- Jonathan Alpern, MD
- Caitlin Eccles-Radtke, MD
- Megan Shaughnessy, MD
- Shawn Haag, M.Ed

#### Unit A: Travel Medicine

- Elizabeth Barnett, MD: Consultant: Lupin Pharmaceuticals; Research Support: Cerexa, Inc.
  Intercell Pharma, ParVax, Inc., DSMB: Pfizer, Inc.; Will discuss off-label/investigative use of: Administration of vaccines in children less than FDA-approved age
- David Bouware, MD: Grant/Research support - GlaxoSmithKline
- Edward Janoff, MD: Grant/Research support - Pfizer, VaxInnate

#### Unit B: Parasites, including malaria, filaria, and nematodes
• Chandy C. John, MD: Will discuss the off-label/investigative use of: Artemisinin
• Jennifer Cope, MD: Will discuss the off-label/investigative use of: Miltefosine (Manufacturer: Paladin, Off-label use: Treatment of free-living ameba infections)
• Susan Montgomery, MD: Will discuss the off-label/investigative use of: The two drugs used to treat Chagas disease, nifurtimox and benznidazole, are not FDA approved and are available in the United States only under IRB-approved protocols and FDA IND mechanism
• Paul T. Cantey, MD, MPH: Will discuss the off-label/investigative use of: Doxycycline and its potential use in ochoceriasis and lymphatic
• Patricia Walker, MD, DTM&H, CTropMed®, FASTMH: Royalties from textbook sales, Elsevier Publishing

Unit C: Bacteria, including tuberculosis, Bartonella, and Brucella

• Sundari Mase, MD: Will discuss the off-label/investigative use of: Fluoroquinolones (Manufacturer: Bayer/Johnson and Johnson, Off-label use: treatment of latent TB infection and TB disease), Second and Thrid-line TB drugs (Manufacturer: various, Off-label use: Treatment of MDR TB)
• M. Patricia Joyce, MD: Will discuss the off-label/investigative use of: Rifampin, ofloxacin, levofloxacin, minocycline used for leprosy treatment
• Sean Shadomy, MD: Will discuss the off-label/investigative use of: Ciprofloxacin and amoxicillin

Unit D: Hemorrhagic Fever and Other Viruses

• David Boulware, MD: Will discuss the off-label/investigative use of: Topics include HIV opportunistic infections, immune reconstitution inflammatory syndrome, and cryptococcal meningititis for which information will be given in regards to international guidelines and published literature for conditions which do

Unit E: Fungi Diagnosis and Treatment Options

• Unit E Faculty had nothing to disclose

3 Original release date: 02/01/2016
4 Recent content review and update: 11/13/2018
5 Content valid through: 11/13/2021
6 *You will have access to the course for which you register for TWO years from the date of your registration. If updated content is published within these two years, the maximum credit count may change.
7 Educational Objectives
Following completion of this activity, learners should be better able to:

• Recognize infectious diseases that affect mobile populations such as refugees, immigrants, and travelers.
• Identify health risks and prevention strategies for international travelers and define vaccine indications for travel-related immunizations.
• Identify methods for diagnosing infectious diseases in international travelers.
• Recognize global migration factors, such as access to care and cultural differences, that impact the diagnosis and treatment of infectious diseases in a global setting.
Example of existing language, may need to update depending on your steps: COMPLETING THIS ONLINE ACTIVITY CONSISTS OF FIVE STEPS:

1. Read all information below
2. Register for the course (see links to 7 sections at the right)
3. Complete the course
4. Complete your course evaluation and feedback
5. Print your Statement of Completion